ImmunoCheckDB: A Comprehensive Platform for Evaluating Cancer Immunotherapy Biomarkers Through Meta-Analyses and Multiomic Profiling

Abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer immunotherapy, but their clinical efficacy varies significantly due to tumor heterogeneity and patient-specific factors. Existing databases lack comprehensive integration of ICI efficacy data and fail to explore biomarkers across pan-cancer contexts, limiting their utility in precision oncology. To address this gap, we developed ImmunoCheckDB, a systematic platform that curates 173 studies on cancer ICI treatment, integrating survival outcomes for traditional and network meta-analyses with multiomic data sets from public repositories, including over 93,000+ individuals across 18 cancer types and 30 ICI regimens to provide a robust resource for pan-cancer biomarker discovery. Equipped with online tools for meta-analysis, network meta-analysis, and multiomic profiling, ImmunoCheckDB enables researchers to investigate correlations between ICI efficacy and molecular biomarkers, featuring key functionalities such as real-time visualization of forest plots, funnel plots, and network diagrams, as well as association analyses linking multiomic data to clinical outcomes. Uniquely combining meta-analytical with multiomic exploration, our platform offers insights into optimal patient populations for ICI therapy, thereby bridging the gap between clinical data and molecular research to empower researchers in advancing precision immunotherapy, with access available at https://smuonco.shinyapps.io/ImmunoCheckDB/ to democratize data-driven insights for personalized cancer treatment.

Keywords

biomarkers / immune checkpoint inhibitors / ImmunoCheckDB / meta-analysis / multi-omics / web tools

References

[1] Z. Gao, Y. Bai, A. Lin, et al., “Gamma Delta T-Cell-Based Immune Checkpoint Therapy: Attractive Candidate for Antitumor Treatment,” Molecular Cancer 22, no. 1 (2023): 31.

[2] J. Liu, M. Ding, J. Bai, et al., “Decoding the Role of Immune T Cells: A New Territory for Improvement of Metabolic-Associated Fatty Liver Disease,” iMeta 2, no. 1 (2023): e76.

[3] D. M. Pardoll, “The Blockade of Immune Checkpoints in Cancer Immunotherapy,” Nature Reviews Cancer 12, no. 4 (2012): 252–264.

[4] Z. Xu, J. Liang, R. Fu, et al., “Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-Small Cell Lung Cancer: A Meta-Analysis Based on Randomised Controlled Trials,” Clinical Oncology 35, no. 10 (2023): 640–651.

[5] A. Snyder, V. Makarov, T. Merghoub, et al., “Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma,” New England Journal of Medicine 371, no. 23 (2014): 2189–2199.

[6] J. Wang, J. Xiu, A. Farrell, et al., “Mutational Analysis of Microsatellite-Stable Gastrointestinal Cancer With High Tumour Mutational Burden: A Retrospective Cohort Study,” Lancet Oncology 24, no. 2 (2023): 151–161.

[7] R. Yi, A. Lin, M. Cao, A. Xu, P. Luo, and J. Zhang, “ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment,” Frontiers in Genetics 11 (2020): 933.

[8] A. Lin, Z. Qiu, J. Zhang, and P. Luo, “Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient With Bladder Cancer,” Frontiers in Immunology 12 (2021): 630773.

[9] M. S. Chatwal, J. Chahoud, and P. E. Spiess, “Revisiting Mechanisms of Resistance to Immunotherapies in Metastatic Clear-Cell Renal-Cell Carcinoma,” Cancer Drug Resistance 6, no. 2 (2023): 314–326.

[10] W. H. Yoon, A. DeFazio, and L. Kasherman, “Immune Checkpoint Inhibitors in Ovarian Cancer: Where Do We Go From Here?,” Cancer Drug Resistance 6, no. 2 (2023): 358–377.

[11] S. Samnani, F. Sachedina, M. Gupta, E. Guo, and V. Navani, “Mechanisms and Clinical Implications in Renal Carcinoma Resistance: Narrative Review of Immune Checkpoint Inhibitors,” Cancer Drug Resistance 6, no. 2 (2023): 416–429.

[12] Z. Liu, Y. Xu, Y. Wang, et al., “Immune-Related Interaction Perturbation Networks Unravel Biological Peculiars and Clinical Significance of Glioblastoma,” iMeta 2, no. 3 (2023): e127.

[13] M. Yarchoan, A. Hopkins, and E. M. Jaffee, “Tumor Mutational Burden and Response Rate to PD-1 Inhibition,” New England Journal of Medicine 377, no. 25 (2017): 2500–2501.

[14] J. Yang, Q. Liu, and Y. Shyr, “A Large-Scale Meta-Analysis Reveals Positive Feedback Between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy,” Cancer Research 84, no. 4 (2024): 626–638.

[15] Q. Lyu, A. Lin, M. Cao, A. Xu, P. Luo, and J. Zhang, “Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition,” Cancer Control 27, no. 1 (2020): 1073274820976665.

[16] L. Liu, Y. Xie, H. Yang, et al., “HPVTIMER: A Shiny Web Application for Tumor Immune Estimation in Human Papillomavirus-Associated Cancers,” iMeta 2, no. 3 (2023): e130.

[17] J. Wu, W. Liu, X. Qiu, et al., “A Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular Carcinoma,” Phenomics 3, no. 6 (2023): 549–564.

[18] A. Anwaier, S. X. Zhu, X. Tian, et al., “Large-Scale Proteomics Data Reveal Integrated Prognosis-Related Protein Signatures and Role of SMAD4 and RAD50 in Prognosis and Immune Infiltrations of Prostate Cancer Microenvironment,” Phenomics 2, no. 6 (2022): 404–418.

[19] D. Morazán-Fernández, J. Mora, and J. A. Molina-Mora, “In Silico Pipeline to Identify Tumor-Specific Antigens for Cancer Immunotherapy Using Exome Sequencing Data,” Phenomics 3, no. 2 (2023): 130–137.

[20] A. B. Haidich, “Meta-Analysis in Medical Research,” Hippokratia 14, no. Suppl 1 (2010): 29–37.

[21] D. M. Caldwell, “An Overview of Conducting Systematic Reviews With Network Meta-Analysis,” Systematic Reviews 3 (2014): 109.

[22] A. El Helali, J. Tao, C. H. L. Wong, et al., “A Meta-Analysis With Systematic Review: Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Advanced Gastric Cancer,” Frontiers in Oncology 12 (2022): 908026.

[23] F. Conforti, L. Pala, V. Bagnardi, et al., “Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-Analysis,” Lancet Oncology 19, no. 6 (2018): 737–746.

[24] C. Chen, F. Zhang, N. Zhou, et al., “Efficacy and Safety of Immune Checkpoint Inhibitors in Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis,” Oncoimmunology 8, no. 5 (2019): e1581547.

[25] X. Jia, H. Xu, L. Geng, et al., “Efficacy and Safety of Neoadjuvant Immunotherapy in Resectable Nonsmall Cell Lung Cancer: A Meta-Analysis,” Lung Cancer 147 (2020): 143–153.

[26] K. Shitara, E. Van Cutsem, Y. J. Bang, et al., “Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial,” JAMA Oncology 6, no. 10 (2020): 1571–1580.

[27] U. Dafni, Z. Tsourti, K. Vervita, and S. Peters, “Immune Checkpoint Inhibitors, Alone or in Combination With Chemotherapy, as First-Line Treatment for Advanced Non-Small Cell Lung Cancer. A Systematic Review and Network Meta-Analysis,” Lung Cancer 134 (2019): 127–140.

[28] J. Y. Wang, J. Xiu, Y. Baca, et al., “Distinct Genomic Landscapes of Gastroesophageal Adenocarcinoma Depending on PD-L1 Expression Identify Mutations in RAS-MAPK Pathway and TP53 as Potential Predictors of Immunotherapy Efficacy,” Annals of Oncology 32, no. 7 (2021): 906–916.

[29] Z. Wang, Q. Zhang, C. Qi, et al., “Combination of AKT1 and CDH1 Mutations Predicts Primary Resistance to Immunotherapy in dMMR/MSI-H Gastrointestinal Cancer,” Journal for Immunotherapy of Cancer 10, no. 6 (2022): e004703.

[30] J. C. Dudley, M. T. Lin, D. T. Le, and J. R. Eshleman, “Microsatellite Instability as a Biomarker for PD-1 Blockade,” Clinical Cancer Research 22, no. 4 (2016): 813–820.

[31] R. Mandal, R. M. Samstein, K. W. Lee, et al., “Genetic Diversity of Tumors With Mismatch Repair Deficiency Influences Anti-PD-1 Immunotherapy Response,” Science 364, no. 6439 (2019): 485–491.

[32] P. Luo, A. Lin, K. Li, T. Wei, and J. Zhang, “DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing,” Journal of Thoracic Oncology 14, no. 12 (2019): e276–e279.

[33] R. K. Owen, N. Bradbury, Y. Xin, N. Cooper, and A. Sutton, “Metainsight: An Interactive Web-Based Tool for Analyzing, Interrogating, and Visualizing Network Meta-Analyses Using R-Shiny and Netmeta,” Research Synthesis Methods 10, no. 4 (2019): 569–581.

[34] J. Wang, W. R. Keusters, L. Wen, and M. M. G. Leeflang, “IPDmada: An R Shiny Tool for Analyzing and Visualizing Individual Patient Data Meta-Analyses of Diagnostic Test Accuracy,” Research Synthesis Methods 12, no. 1 (2021): 45–54.

[35] A. Lin, C. Qi, T. Wei, et al., “CAMOIP: A Web Server for Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-Cancer,” Briefings in Bioinformatics 23, no. 3 (2022): bbac129.

[36] Z. Zeng, C. J. Wong, L. Yang, et al., “TISMO: Syngeneic Mouse Tumor Database to Model Tumor Immunity and Immunotherapy Response,” Nucleic Acids Research 50, no. D1 (2022): D1391–D1397.

[37] L. C. Brown, M. D. Tucker, R. Sedhom, et al., “LRP1B Mutations Are Associated With Favorable Outcomes to Immune Checkpoint Inhibitors Across Multiple Cancer Types,” Journal for Immunotherapy of Cancer 9, no. 3 (2021): e001792.

[38] H. Feng, N. Chen, H. Li, et al., “Pan-Cancer Analysis of the Immune Aspects and Prognostic Value of NCAPG2,” Heliyon 9, no. 7 (2023): e18051.

[39] M. Lu, B. Zhao, M. Liu, et al., “Pan-Cancer Analysis of SETD2 Mutation and Its Association With the Efficacy of Immunotherapy,” NPJ Precision Oncology 5, no. 1 (2021): 51.

[40] Y. M. Sun, Y. Wang, X. X. Sun, J. Chen, Z. P. Gong, and H. Y. Meng, “Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-Small-Cell Lung Cancer Patients: A Meta-Analysis,” Frontiers in Oncology 10 (2020): 558454.

[41] S. Wang, Y. Li, Z. Liu, et al., “Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Combined With Chemotherapy for Extensive-Stage Small Cell Lung Cancer: A Network Meta-Analysis,” Lung Cancer 178 (2023): 47–56.

[42] M. M. Mukaka, “Statistics Corner: A Guide to Appropriate Use of Correlation Coefficient in Medical Research,” Malawi Medical Journal: The Journal of Medical Association of Malawi 24, no. 3 (2012): 69–71.

[43] J. H. Kim, J. Shim, M. J. Ji, et al., “The Condensin Component NCAPG2 Regulates Microtubule-Kinetochore Attachment Through Recruitment of Polo-Like Kinase 1 to Kinetochores,” Nature Communications 5 (2014): 4588.

[44] C. Shi, K. Qin, A. Lin, et al., “The Role of DNA Damage Repair (DDR) System in Response to Immune Checkpoint Inhibitor (ICI) Therapy,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 268.

[45] Q. Wang, Z. Li, S. Zhou, et al., “NCAPG2 Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Pancreatic Cancer Validation,” Frontiers in Immunology 14 (2023): 1097403.

[46] J. Yang, Q. Liu, and Y. Shyr, “A Large-Scale Meta-Analysis Reveals Positive Feedback Between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy,” Cancer Research (2023).

[47] C. Chen, H. Liu, Q. Xu, X. Zhang, F. Mu, and J. Liu, “Association of PTPRT Mutations With Cancer Metastasis in Multiple Cancer Types,” BioMed Research International 2022 (2022): 9386477.

[48] X. Li, X. Yan, Y. Wang, B. Kaur, H. Han, and J. Yu, “The Notch Signaling Pathway: A Potential Target for Cancer Immunotherapy,” Journal of Hematology & Oncology 16, no. 1 (2023): 45.

[49] H. J. Liu, H. Du, D. Khabibullin, et al., “mTORC1 Upregulates B7-H3/CD276 to Inhibit Antitumor T Cells and Drive Tumor Immune Evasion,” Nature Communications 14, no. 1 (2023): 1214.

[50] Z. Wang, J. Zhao, G. Wang, et al., “Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade,” Cancer Research 78, no. 22 (2018): 6486–6496.

[51] D. Welcker, M. Jain, S. Khurshid, et al., “AATF Suppresses Apoptosis, Promotes Proliferation and Is Critical for Kras-Driven Lung Cancer,” Oncogene 37, no. 11 (2018): 1503–1518.

[52] W. K. Hamilton, MAVIS: Meta-Analysis via Shiny (R package, Version 1.1. 3). https://CRAN.R-project.org/package=MAVIS.

[53] Y. Liu, Y. Zhang, W. Xie, et al., IMPACT: A Web Server for Exploring Immunotherapeutic Predictive and Cancer Prognostic Biomarkers. bioRxiv. 2023:2023.01.31.526401.

[54] D. Y. Wang, F. Ye, S. Zhao, and D. B. Johnson, “Incidence of Immune Checkpoint Inhibitor-Related Colitis in Solid Tumor Patients: A Systematic Review and Meta-Analysis,” Oncoimmunology 6, no. 10 (2017): e1344805.

[55] E. Soularue, P. Lepage, J. F. Colombel, et al., “Enterocolitis Due to Immune Checkpoint Inhibitors: A Systematic Review,” Gut 67, no. 11 (2018): 2056–2067.

[56] G. T. Gibney, L. M. Weiner, and M. B. Atkins, “Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy,” Lancet Oncology 17, no. 12 (2016): e542–e551.

[57] M. Yang, Y. R. Miao, G. Y. Xie, et al., “ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics From Transcriptome Profiles,” Cancer Immunology Research 10, no. 11 (2022): 1398–1406.

[58] M. A. Postow, R. Sidlow, and M. D. Hellmann, “Immune-Related Adverse Events Associated With Immune Checkpoint Blockade,” New England Journal of Medicine 378, no. 2 (2018): 158–168.

[59] M. Nishino, L. M. Sholl, H. Hatabu, N. H. Ramaiya, and F. S. Hodi, “Anti-PD-1-Related Pneumonitis During Cancer Immunotherapy,” New England Journal of Medicine 373, no. 3 (2015): 288–290.

[60] M. Nishino, N. H. Ramaiya, M. M. Awad, et al., “PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course,” Clinical Cancer Research 22, no. 24 (2016): 6051–6060.

[61] J. Herrmann, “Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia,” Nature Reviews Cardiology 17, no. 8 (2020): 474–502.

[62] S. Xu, U. C. Sharma, C. Tuttle, and S. Pokharel, “Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-Clinical Models and Clinical Studies,” Frontiers in Cardiovascular Medicine 8 (2021): 619650.

[63] J. M. Bland, “Statistics Notes: The Odds Ratio,” BMJ 320, no. 7247 (2000): 1468.

[64] C. Andrade, “Understanding Relative Risk, Odds Ratio, and Related Terms: As Simple as It Can Get,” Journal of Clinical Psychiatry 76, no. 7 (2015): e857–e861.

[65] P. Cummings, “The Relative Merits of Risk Ratios and Odds Ratios,” Archives of Pediatrics & Adolescent Medicine 163, no. 5 (2009): 438–445.

[66] A. J. Viera, “Odds Ratios and Risk Ratios: What's the Difference and Why Does It Matter?,” Southern Medical Journal 101, no. 7 (2008): 730–734.

[67] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring Inconsistency in Meta-Analyses,” BMJ 327, no. 7414 (2003): 557–560.

[68] M. Marcucci, I. Etxeandia-Ikobaltzeta, S. Yang, et al., “Benefits and Harms of Direct Oral Anticoagulation and Low Molecular Weight Heparin for Thromboprophylaxis in Patients Undergoing Non-Cardiac Surgery: Systematic Review and Network Meta-Analysis of Randomised Trials,” BMJ 376 (2022): e066785.

[69] A. Pérez-Millan, J. Contador, R. Tudela, et al., “Evaluating the Performance of Bayesian and Frequentist Approaches for Longitudinal Modeling: Application to Alzheimer's Disease,” Scientific Reports 12, no. 1 (2022): 14448.

[70] S. Balduzzi, G. Rücker, and G. Schwarzer, “How to Perform a Meta-Analysis With R: A Practical Tutorial,” Evidence Based Mental Health 22, no. 4 (2019): 153–160.

[71] S. Balduzzi, G. Rücker, A. Nikolakopoulou, et al., “Netmeta: An R Package for Network Meta-Analysis Using Frequentist Methods,” Journal of Statistical Software 106 (2023): 1–40.

[72] H. Wickham, “ggplot2,” WIREs Computational Statistics 3, no. 2 (2011): 180–185.

[73] A. Liberzon, C. Birger, H. Thorvaldsdóttir, M. Ghandi, J. P. Mesirov, and P. Tamayo, “The Molecular Signatures Database Hallmark Gene Set Collection,” Cell Systems 1, no. 6 (2015): 417–425.

[74] R. L. Grossman, A. P. Heath, V. Ferretti, et al., “Toward a Shared Vision for Cancer Genomic Data,” New England Journal of Medicine 375, no. 12 (2016): 1109–1112.

[75] J. Gao, B. A. Aksoy, U. Dogrusoz, et al., “Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal,” Science Signaling 6, no. 269 (2013): pl1.

[76] C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson, R. Beroukhim, and G. Getz, “GISTIC2.0 Facilitates Sensitive and Confident Localization of the Targets of Focal Somatic Copy-Number Alteration in Human Cancers,” Genome Biology 12, no. 4 (2011): R41.

[77] V. Thorsson, D. L. Gibbs, S. D. Brown, et al., “The Immune Landscape of Cancer,” Immunity 51, no. 2 (2019): 411–412.

[78] A. Subramanian, P. Tamayo, V. K. Mootha, et al., “Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles,” Proceedings of the National Academy of Sciences 102, no. 43 (2005): 15545–15550.

[79] D. A. Barbie, P. Tamayo, J. S. Boehm, et al., “Systematic RNA Interference Reveals That Oncogenic KRAS-Driven Cancers Require TBK1,” Nature 462, no. 7269 (2009): 108–112.

[80] S. Hänzelmann, R. Castelo, and J. Guinney, “GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data,” BMC Bioinformatics 14 (2013): 7.

[81] B. Ru, C. N. Wong, Y. Tong, et al., “TISIDB: An Integrated Repository Portal for Tumor-Immune System Interactions,” Bioinformatics 35, no. 20 (2019): 4200–4202.

[82] Y. Jing, J. Liu, Y. Ye, et al., “Multi-Omics Prediction of Immune-Related Adverse Events During Checkpoint Immunotherapy,” Nature Communications 11, no. 1 (2020): 4946.

[83] F. E. Harrell and C. Dupont, Hmisc: Harrell Miscellaneous. https://hbiostat.org/R/Hmisc/.

[84] W. Chang, J. Cheng, J. J. Allaire, C. Sievert, B. Schloerke, and Y. Xie, Shiny: Web Application Framework for R: Web Application Framework, 2017. https://cran.r-project.org/web/packages/shiny/index.html.

[85] M. B. Hoy, “HTML5: A New Standard for the Web,” Medical Reference Services Quarterly 30, no. 1 (2011): 50–55.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).